Real-time index price for S&P 500 Financials [Sector] (SRFI), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

Wall St. Insights The seemingly endless political season is almost over. It’s possible we won’t know the winner for a while.

JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 ...

The company reported $11.9B in revenue for the quarter with ~8% YoY growth as its blockbuster drugs Revlimid and Eliquis surpassed expectations, while sales from cancer therapy Opdivo slightly ...

Also Read: Bristol Myers’ $10B Cancer Drug Opdivo Scores Expanded Use FDA Approval For Lung Cancer In Pre And Post-Surgery Setting Opdivo sales increased 4% to $2.36 billion, and global sales ...

If you type “laptops under $500” into any search bar, you’ll be faced with a flood of results. Although you’ll see a lot of options, most aren’t worth the price, no matter the discount.

Growth portfolio primarily comprises sales from immuno-oncology drugs like Opdivo, Orencia, Yervoy, Reblozyl, Opdualag, ...

It nudges the body’s inherent defence mechanism to take on the invading cells. That is the reason why Keytruda and other drugs like Opdivo (nivolumab) of Bristol Myers Squibb are categorised as ...

The firm sees growth headwinds from the Eliquis and Opdivo loss of exclusivities. Bristol is in a transition period from 2025 through 2027, which will likely add volatility, the analyst tells ...